The earnings call highlighted strong clinical trial results and a solid financial position, with significant potential for future growth. However, this is tempered by restructuring costs and increased net losses.

Company Guidance -

Q3 2025

During the ADC Therapeutics SA Q2 2025 earnings call, the company reported net product revenues of $18.1 million for the second quarter and $35.5 million for the first half of the year, both slightly exceeding the prior year's figures. Promising clinical data from the LOTIS-7 trial were highlighted, with a 93.3% overall response rate and an 86.7% complete response rate in 30 efficacy-evaluable DLBCL patients. The company plans to expand enrollment to 100 patients at a 150-microgram per kilogram dose, aiming for regulatory discussions and compendia strategies. The LOTIS-5 trial remains on track to reach the prespecified number of progression-free survival events by the end of 2025, with potential peak sales of $200 million to $300 million. ADC Therapeutics completed a $100 million private placement, extending its cash runway into 2028, and announced a strategic plan to streamline operations, including a 30% reduction in global workforce. Overall, the company anticipates ZYNLONTA could reach peak U.S. revenues of $600 million to $1 billion.

Promising ZYNLONTA Combination Data

ZYNLONTA in combination with glofitamab showed an overall response rate of 93.3% and a complete response rate of 86.7% across 30 efficacy-evaluable DLBCL patients. 25 of the 26 patients achieving CR remained in CR as of the data cutoff.

Record Cash Position and Extended Runway

Cash and cash equivalents were $264.6 million as of June 30, 2025, up from $194.7 million at March 31, 2025. The cash runway now extends into 2028.

Potential to Transform Lymphoma Treatment

ZYNLONTA has the potential to reach peak revenues of $600 million to $1 billion in the U.S., with opportunities in second line plus DLBCL and indolent lymphomas.

Positive Phase II IIT Data in Marginal Zone Lymphoma

Updated data from the Phase II IIT in marginal zone lymphoma showed an overall response rate of 85% and a complete response rate of 69%.

ADC Therapeutics (ADCT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADCT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.35 / -	-0.42	―	―	―
Aug 12, 2025	2025 (Q2)	-0.49 / -0.50	-0.38	-31.58% (-0.12)
May 14, 2025	2025 (Q1)	-0.40 / -0.36	-0.56	35.71% (+0.20)
Mar 27, 2025	2024 (Q4)	-0.41 / -0.29	-1.03	71.84% (+0.74)
Nov 07, 2024	2024 (Q3)	-0.40 / -0.42	-0.58	27.59% (+0.16)
Aug 06, 2024	2024 (Q2)	-0.46 / -0.38	-0.58	34.48% (+0.20)
May 06, 2024	2024 (Q1)	-0.56 / -0.56	-0.74	24.32% (+0.18)
Mar 13, 2024	2023 (Q4)	-0.50 / -1.03	-0.3	-243.33% (-0.73)
Nov 07, 2023	2023 (Q3)	-0.63 / -0.58	-0.65	10.77% (+0.07)
Aug 08, 2023	2023 (Q2)	-0.70 / -0.58	-0.84	30.95% (+0.26)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ADCT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$2.68	$2.94	+9.70%
May 14, 2025	$1.32	$1.81	+37.12%
Mar 27, 2025	$1.58	$1.52	-3.80%
Nov 07, 2024	$3.20	$2.93	-8.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ADC Therapeutics Ltd (ADCT) report earnings?

ADC Therapeutics Ltd (ADCT) is schdueled to report earning on Nov 11, 2025, Before Open (Confirmed).

What is ADC Therapeutics Ltd (ADCT) earnings time?

ADC Therapeutics Ltd (ADCT) earnings time is at Nov 11, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ADCT EPS forecast?

ADCT EPS forecast for the fiscal quarter 2025 (Q3) is -0.35.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing